Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 479 results found since Jan 2013.

Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi).[1] The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.[2] It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Gene-editing summit touts sickle cell success, while questions on embryo editing linger
After decades of living with often excruciating pain, Victoria Gray had to get used to a new sensation in recent years: waking up without it. “It may sound crazy, but I had to pinch myself to see was I still able to feel pain,” she says. Gray, a 37-year-old mother of four from Forest, Mississippi, who was born with sickle cell disease, arguably became the star of last week’s International Summit on Human Genome Editing in London when she spoke about her transformation. In 2019, she was the first person to undergo an experimental therapy in which blood stem cells were taken from her, altered with the ...
Source: Science of Aging Knowledge Environment - March 13, 2023 Category: Geriatrics Source Type: research

The Fear
When I was 14, my immune system started down its deep,dark path toward permanent dysfunction. It started with a bump,a small red itchy bump that turned into dozens & dozens of bumps in a raised rash that marched up my left arm, across the left side of my chest,down my left armpit & across my back. And then those bumps swelled up,with a yellowish disgusting gunk..to the point of bursting. At that point,convinced that I had cancer, I told my parents & they took me to the doctor.The diagnosis was immeadiete & straightforward."You have the shingles."Isn't that something older people get? Well,yes, but anyone who has had the go...
Source: The D-Log Cabin - January 24, 2013 Category: Diabetes Authors: HVS Source Type: blogs

HPV Vaccines Can Kill And They Do!
Conclusion Just from the evidence that I have provided, HPV vaccines clearly are not safe, and yet no government to date has ever banned these vaccines. Other products have been banned for far less dangers, so why is a vaccine that has killed 140 women and children and maimed thousands of others been allowed to stay on the market? To offer the HPV vaccine to newborn babies along with the hepatitis B vaccine is pure evil. Many babies are born prematurely and we have to ask ourselves what the impact of these two highly dangerous and toxic vaccines given at the same time will be. We also need to question why newborn babies ne...
Source: vactruth.com - August 10, 2013 Category: Health Medicine and Bioethics Commentators Authors: Christina England Tags: Christina England Top Stories Writers Adverse Events Cervarix gardasil Hepatitis B vaccine HPV Vaccine Vaccine Death VAERS Source Type: blogs

HPV vaccine could be offered to boys
"HPV vaccine could be given to boys as well as girls in UK," The Guardian reports. It goes on to say that, "Government advisers are to consider whether the HPV vaccine, routinely offered to girls at the ages of 12 and 13 since 2008 to help protect them against cervical cancer, should also be offered to boys and some men". The news appears to be based on draft minutes from the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI advises the government on how vaccinations may reduce health problems – and considers the evidence on factors such as the prevalence of diseases, and the safety ...
Source: NHS News Feed - November 29, 2013 Category: Consumer Health News Tags: Pregnancy/child Medication QA articles Cancer Source Type: news

Mind the gaps: a qualitative study of perceptions of healthcare professionals on challenges and proposed remedies for cervical cancer help-seeking in post conflict northern Uganda
Conclusions: Operational level healthcare professionals in northern Uganda reported several practical challenges facing cervical cancer care that influence their decisions, management goals and practices. The challenges and proposed remedies can inform targeted interventions for early detection, management, and control of cervical cancer in Uganda.
Source: BMC Family Practice - December 17, 2013 Category: Primary Care Authors: Amos MwakaHenry WabingaHarriet Mayanja-Kizza Source Type: research

Bombshell TV Show About HPV Vaccines Reveals Cruel Nature of Vaccine Pushers
Conclusion More and more are people reaching each other from all corners of the world and sharing their sorrow because of the HPV vaccines. They receive comfort and information from knowledgeable and sympathetic people who genuinely care. [9] Many of those who are helping have expert and unbiased knowledge of the vaccines. The numbers of voices of those who are suffering in anguish and despair because of the HPV vaccines are growing rapidly day by day. The world is hearing them now.   References 1. http://katiecouric.com/videos/category/120413-the-hpv-vaccine-conversation-rosie-perez/ 2. http://katiecouric.com/feature...
Source: vactruth.com - January 29, 2014 Category: Health Medicine and Bioethics Commentators Authors: Sandy Lunoe Tags: Sandy Lunoe Top Stories Adverse Reaction Cervarix gardasil HPV Vaccine Vaccine Death Source Type: blogs

A randomized,multicenter,placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small-cell-lung cancer patients.
CONCLUSIONS: Switch maintenance with racotumomab-alum is an effective and well tolerated treatment option for advanced NSCLC patients. PMID: 24788102 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 1, 2014 Category: Cancer & Oncology Authors: Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M, Viada C, Mendoza IC, Guerra PP, Garcia E, Ortiz RA, de la Torre AV, Cepeda M, Perez K, Chong E, Hernandez AM, Toledo D, Gonzalez Z, Mazorra Z, Crombet T, Perez R, Vazquez AM, Ma Tags: Clin Cancer Res Source Type: research

Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus.
CONCLUSIONS: In a population referred for symptoms of orthostatic intolerance and other symptoms consistent with autonomic dysfunction that began in close temporal association with a quadrivalent HPV vaccination, we identified a 60% prevalence of POTS. Further work is urgently needed to elucidate the potential for a causal link between the vaccine and circulatory abnormalities and to establish targeted treatment options for the affected patients. PMID: 25882168 [PubMed - as supplied by publisher]
Source: Vaccine - April 13, 2015 Category: Allergy & Immunology Authors: Brinth LS, Pors K, Theibel AC, Mehlsen J Tags: Vaccine Source Type: research